Heart attack

December 24, 2017

Combinatorial therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Matrine, Epicatechin, 14, 15, Epoxyeicosatrienoicacids (14, 15 EETs) (MEEET)  decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 25/December/2017, 1.37 am

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical […]
December 23, 2017

Molecular therapy for Cardiomyopathy: Lycopene (LYC), isolated from Gac, Guava, and Tomatoes, among others, decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 24/December/2017,  12.51 am

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart […]
December 22, 2017

Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 23/December/2017, 2.13 am

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical […]
December 19, 2017

Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 19/December/2017, 10.54 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses […]